{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.5","upperLimit":"20.2","value":"9.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"The time on investigational product (including dose interruptions) is defined as the difference between the date of the last dose of investigational product and the date of the first dose of investigational product plus one.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants received pazopanib 800 milligrams (mg) once daily.","id":"OG000","title":"Pazopanib 800 mg"}],"paramType":"MEDIAN","populationDescription":"ATS Population","reportingStatus":"POSTED","timeFrame":"From Baseline to investigational product discontinuation (up to 6.230 years)","title":"Median Time on Investigational Product","type":"PRIMARY","unitOfMeasure":"Months"}